According to a statement from the company’s President and CEO Nikolaj Sørensen, “Orexo has developed Zubsolv as a novel sublingual therapy meeting the needs of millions of patients that suffers from opioid dependence to offer them a new choice of treatment. Zubsolv has in previous studies showed a high acceptability compared to the leading treatment modalities in the market.”
The latest National Survey on Drug Use and Health (NSDUH) stated that roughly 2.2 million people aged 12 or older in the U.S. deal with abuse or dependence on opiates such as heroin or prescription painkillers, though Orexo estimates that number to be more than twice as many. There has also been the recent news from the CDC stating that the number of overdose deaths from opioid pharmaceuticals has increased exponentially in the past decade.
Many people addicted to opiates have cited the agonizing withdrawal symptoms as being deterrents for trying to stop using them. This, along with cost and bed availability continue to be major blocks for this subgroup of drug abusers.
Hopefully having more treatment options available for people struggling with opioid abuse or addiction will encourage them to seek help. If you have a loved one in need of drug or alcohol rehabilitation, contact Family First Intervention to learn more about our treatment referral and intervention services.